title: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis.
abstract: We compared the efficacy and the long-term effects of nocturnal hemodialysis (NHD) versus conventional hemodialysis (CHD) in controlling serum phosphate levels in patients with end-stage renal disease (ESRD). Patients underwent thrice weekly CHD and were subsequently switched to NHD six nights weekly. In the "acute" study serum and dialysate phosphate were measured during and after dialysis, and the total dialysate was collected to calculate mass solute removal. Although pre-dialysis (1.7 +/- 0.6 vs. 1.5 +/- 0.8 mM) serum phosphate levels were similar in CHD and NHD, respectively, post-dialysis levels were slightly lower with CHD (0.7 +/- 0.2 vs. 0.8 +/- 0.2 mM, P < 0.05). The measured phosphate removed per session of CHD or NHD was comparable, 25.3 +/- 7.5 versus 26.9 +/- 9.8 mumol/session, respectively. On the other hand, the cumulative weekly phosphate removal was significantly higher with NHD as compared to CHD, 75.8 +/- 22.5 versus 161.6 +/- 59.0 mumol/week (P < 0.01). In the "chronic" study serum phosphate levels were measured monthly for five months on CHD and for five months after the patients were switched to NHD. Dietary phosphate intake and the dosage of phosphate binders were tabulated. Serum phosphate levels fell during NHD: 2.1 +/- 0.5 mM at the beginning of the study and 1.3 +/- 0.2 mM five months after being switched to NHD (P < 0.001). At the same time dietary phosphate intake increased by 50%. By the fourth month of NHD therapy none of the patients was taking any phosphate binders. In conclusion, NHD is more effective in controlling serum phosphate levels than CHD, allowing patients to discontinue their phosphate binders completely and to ingest a more liberal diet.
authors.affiliation: Wellesley Central Hospital, University of Toronto, Canada.
authors.forename: I
authors.initials: I
authors.lastname: Mucsi
authors.forename: G
authors.initials: G
authors.lastname: Hercz
authors.forename: R
authors.initials: R
authors.lastname: Uldall
authors.forename: M
authors.initials: M
authors.lastname: Ouwendyk
authors.forename: R
authors.initials: R
authors.lastname: Francoeur
authors.forename: A
authors.initials: A
authors.lastname: Pierratos
mesh_terms: D018592:Cross-Over Studies; D004032:Diet; D005260:Female; D006437:Hemodialysis, Home / Q000379:methods*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D010710:Phosphates / Q000008:administration & dosage / Q000097:blood* / Q000302:isolation & purification; D013997:Time Factors
chemical_list: D010710:Phosphates